- "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" -
Toronto Stock Exchange Symbol: MS
EDMONTON, May 14 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
Mr. Richard Brown, Vice President, Commercial Development, BioMS Medical and
Mr. Jack Tupman, Senior Director, Corporate Business Development, Eli Lilly
and Company, will take part in a Technology Transfer/Licensing session at the
BIO International Convention 2009 in Atlanta, Georgia entitled "BioMS/Eli
Lilly - Dissecting a Billion Dollar Collaboration."
Also participating in the panel session will be Mr. Nitin Kaushal,
Director, Healthcare Investment Banking, Desjardins Securities and Mr. Jeremy
Webster, Senior VP & Director Deloitte & Touche, LLP. The moderator for the
session will be Ms. Cheryl Reicin, Partner, Torys LLP.
WHEN: Thursday May 21st at 8:00am (Eastern Time)
WHERE: Room B316, Georgia World Congress Center, Atlanta, Georgia
BioMS Medical will also provide a corporate presentation at the Business
Forum at 9:40am (Eastern Time) on Wednesday May 20th.
About BIO International Convention
The BIO International Convention, hosted by the Biotechnology Industry
Organization, is the largest global event for the biotechnology industry and
attracts the biggest names in biotech, offers key networking and partnering
opportunities, and provides insights and inspiration on major trends affecting
the industry. For more information visit http://convention.bio.org/.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, dirucotide, is for the treatment of multiple sclerosis and is
being evaluated in two pivotal phase III clinical trials for Secondary
Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company exclusive worldwide
rights to dirucotide in exchange for an $87 million upfront payment, milestone
payments and escalating royalties on sales. For further information please
visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that dirucotide will continue to demonstrate a satisfactory
safety profile in ongoing and future clinical trials; and that BioMS Medical
Corp. will complete the respective clinical trials within the timelines
communicated in this release. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information:
For further information: Tony Hesby, Ryan Giese, Amanda Stadel, BioMS
Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail:
firstname.lastname@example.org, Internet: http://www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: